Approval Status
Approved December 1997

Treatment for
rejection of kidney transplants

Diabetes / Endocrinology , Urology & Kidneys

Hoffman-La Roche's new monoclonal antibody drug, Zenapax (daclizumab), has been approved to prevent rejection of kidney transplants. The drug uses the body's own immune system to prevent the acute rejection that can make kidney transplants fail.

The FDA said its approval was based on two clinical trials that showed Zenapax significantly reduced acute rejections in patients who got the drug along with the standard three-drug cocktail of immunosuppressant drugs. Patients on Zenapax had 37 to 40% fewer rejections episodes than those given an inert placebo.

Zenapax Drug Information

The Zenapax drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top